Health TrialsbyHealthPanel

Efficacy of Serratus Anterior Plane Block With Dexmedetomidine During Breast Surgery

ConditionAnalgesia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-65
SponsorNational Cancer Institute, Egypt

About this trial

This study aims to compare single level serratus block versus bilevel serratus block with and without dexmedetomidine in cancer patients undergoing modified radical mastectomy for breast cancer regarding pain control and possible side effects.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients scheduled for modified radical mastectomy,

Age 18-65 years,

ASA I-II

Disqualifiers

patient refusal,

coagulation defects,

abnormal kidney or liver functions,

local infection at site of injection.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Single level serratus anterior plane block

    Procedure/Surgery

    Serratus anterior plane block with local anesthetics at the third rib

  • Single level serratus anterior plane block with dexmedetomidine

    Procedure/Surgery

    Serratus anterior plane block with local anesthetics and dexmedetomidine at the third rib

  • Bilevel serratus anterior plane block

    Procedure/Surgery

    Serratus anterior plane block with local anesthetics at the third and fifth rib

  • Bilevel serratus anterior plane block with dexmedetomidine

    Procedure/Surgery

    Serratus anterior plane block with local anesthetics and dexmedetomidine at the third and fifth rib

Treatment groups

172 Participants
are divided into 4 treatment groups
Group A: Single level serratus anterior plane blockActive comparator 1 intervention
Group B: Single level serratus anterior plane block with dexmedetomidineExperimental treatment 1 intervention
Group C: Bilevel serratus anterior plane blockExperimental treatment 1 intervention
Group D: Bilevel serratus anterior plane block with dexmedetomidineExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

First time to receive analgesia

first time to receive morphine analgesia in hours

Time frame
First 24 hours postoperatively
2

Total analgesic requisite

total amount of morphine consumption in the first 24 hours postoperatively in mg

Time frame
First 24 hours postoperatively

Secondary outcomes

1

Pain scores

pain scores will be assessed using Visual Analogue Scale on a sale from 0 to 10 with 0 meanung no pain and 10 meaning severe pain

Time frame
First 24 hours postoperatively
2

Side effects

nausea and vomiting and hematoma at site of injection

Time frame
First 24 hours postoperatively
3

Perioperative heart rate values

heart rate values in the form of beat per minute in the perioperative period including preoperative, intraoperative and postoperative

Time frame
First 24 hours
4

Mean arterial blood pressure

Mean arterial blood pressure values in the form mmHg in the perioperative period including preoperative, intraoperative and postoperative

Time frame
First 24 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

National Cancer Institute, Egypt

Lead sponsor

Source ClinicalTrials.gov
Apply now